SCHEMBL6843558

SCHEMBL6843558

Cc1ccc(C(N)=S)c(F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
RAD52 P43351 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
DGAT1 O75907 1/20 0.37
MAP2K2 P36507 1/20 0.37
MAP2K1 Q02750 1/20 0.37
CYP1A2 P05177 1/20 0.36
CSNK2A1 P68400 1/20 0.35
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NFE2L2 Q16236 1/20 0.34
MAPT P10636 1/20 0.34
CPS1 P31327 2/20 0.34
GRM2 Q14416 1/20 0.34
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27721595 0.81 CSNK2A1 (0.41) LOXL2GAACSNK2A1NFE2L2CPS1
SCHEMBL20560315 0.79 LOXL2 (0.38) LOXL2GAAHTTCSNK2A1NFE2L2
SCHEMBL1003133 0.79 DGAT1 (0.60) LOXL2DGAT1MAP2K2MAP2K1CSNK2A1
SCHEMBL8234925 0.79 F2 (0.49) ALDH1A1LOXL2DGAT1MAP2K2MAP2K1
SCHEMBL2034076 0.78 CES2 (0.56) ALDH1A1HPGDRAD52GAAHTT
SCHEMBL10147428 0.78 TDP1 (0.44) ALDH1A1HPGDRAD52GAAKDM4E
SCHEMBL14800110 0.78 ALDH1A1 (0.48) ALDH1A1HPGDGAAKDM4EHTT
SCHEMBL28822007 0.78 PARP1 (0.42) ALDH1A1HPGDRAD52GAAKDM4E
Hydrochloric Acid SCHEMBL4090389 0.78 DGAT1 (0.58) LOXL2DGAT1MAP2K2MAP2K1CSNK2A1
SCHEMBL3666515 0.77 ALDH1A1 (0.42) ALDH1A1HPGDRAD52GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077659-A1 Method for treating ppar gamma mediated diseases or conditions SMITHKLINE BEECHAM CORPORATION 2004-04-22 US disclosed
EP-1368011-A1 METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES SmithKline Beecham Corporation (US) 2003-12-10 EP disclosed
WO-2002067912-A2 METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS SMITHKLINE BEECHAM CORPORATION (US) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077659-A1 Method for treating ppar gamma mediated diseases or conditions PPARG, PPARA, PPARD ALDH1A1 1219/4885HPGD 409/4885RAD52 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.